Ravandi Farhad, Stone Richard
The University of Texas M.D. Anderson Cancer Center, Houston, TX.
Dana-Farber/Brigham and Women's Cancer Center, Boston, MA.
Clin Lymphoma Myeloma Leuk. 2017 Sep;17(9):543-544. doi: 10.1016/j.clml.2017.06.037. Epub 2017 Jul 6.
Treatment of patients with acute promyelocytic leukemia has significantly improved with the introduction of target specific agents all-trans retinoic acid (ATRA) and arsenic trioxide (ATO) with long term survival a reality for the majority of patients. This can serve as a paradigm for cancer therapy where with the introduction of more potent target-specific drugs our reliance on the traditional cytotoxic agents is likely to diminish and less toxic and more effective regimens are likely to replace the current intensive chemotherapy regimens.
随着靶向特异性药物全反式维甲酸（ATRA）和三氧化二砷（ATO）的引入，急性早幼粒细胞白血病患者的治疗有了显著改善，大多数患者实现了长期生存。这可以作为癌症治疗的一个范例，随着更有效的靶向特异性药物的引入，我们对传统细胞毒性药物的依赖可能会减少，毒性更小、更有效的治疗方案可能会取代当前的强化化疗方案。
